Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00675350 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors
A Phase 1 study of Hematologic Tumors, sponsored by ChemGenex Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT00675350: Completed Phase 1 study of Hematologic Tumors, sponsored by ChemGenex Pharmaceuticals.
NCT00675350 is a Phase 1 study of Hematologic Tumors that has completed, run by ChemGenex Pharmaceuticals. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00675350, a Phase 1 study of Hematologic Tumors, has completed, sponsored by ChemGenex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
PK Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors
Conditions Studied
Interventions
- DRUG Omacetaxine
Study Locations (1)
Texas
- Mary Crowley Cancer Research Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
What the finished NCT00675350 record still lists
NCT00675350 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Hematologic Tumors appearing as the primary indexed condition, and to 1 intervention - of which Omacetaxine is the first listed.
NCT00675350 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00675350 about?
NCT00675350 is a clinical study titled "Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors". PK Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors
What is the current status of trial NCT00675350?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2008-04. Estimated completion is 2009-01.
What conditions does trial NCT00675350 study?
This clinical trial studies the following conditions: Hematologic Tumors.
What interventions are being tested in trial NCT00675350?
The interventions under investigation include: Omacetaxine (DRUG).
Who is sponsoring clinical trial NCT00675350?
This trial is sponsored by ChemGenex Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00675350 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00675350's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia